Longevity

Intermittent schedules, exercise timing, and the mixture of animal research, mechanistic reasoning, and repetition that shaped today's community conventions.

Elamipretide is now an approved drug for one rare disease at a specific dose — yet the longevity community researches it at very different, usually lower amounts. The gap between the label and the practice is the story.

If mitochondrial decline sits near the center of aging, the interesting question is how researchers are trying to address it. The research splits into three distinct strategies — protect the structure, restore the metabolic inputs, and strengthen the signals — and seeing them together is the best map of the field.

They are both mitochondrial peptides, and they are almost opposites — one a natural signal that tells cells to adapt, the other a synthetic molecule that physically stabilizes the membrane. Comparing them is the clearest way to see how many angles mitochondrial medicine really has.

NAD+ sits at the center of how cells make energy and repair themselves, and it appears to fall with age. That has made raising it one of the most pursued ideas in longevity — and one of the most instructive tests of how biology translates from mice to people.

Most mitochondrial strategies work on signaling or fuel. SS-31 does something more structural — it binds the lipid that holds the energy machinery together. In 2025 it became the first mitochondria-targeted drug the FDA has ever approved.

Mitochondria do far more than make energy — and their gradual dysfunction sits close to the center of why bodies age. A guide to the biology that has made mitochondria one of the most important targets in longevity research.

A tiny peptide encoded inside the mitochondria may help explain how our cells adapt to exercise and metabolic stress — and it is opening a fascinating window into the biology of aging.